247 related articles for article (PubMed ID: 24282275)
1. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
Slee RB; Grimes BR; Bansal R; Gore J; Blackburn C; Brown L; Gasaway R; Jeong J; Victorino J; March KL; Colombo R; Herbert BS; Korc M
Mol Cancer Ther; 2014 Feb; 13(2):307-315. PubMed ID: 24282275
[TBL] [Abstract][Full Text] [Related]
2. Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.
Hiruma Y; Koch A; Hazraty N; Tsakou F; Medema RH; Joosten RP; Perrakis A
J Biol Chem; 2017 Sep; 292(35):14496-14504. PubMed ID: 28726638
[TBL] [Abstract][Full Text] [Related]
3. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.
Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A
Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303
[TBL] [Abstract][Full Text] [Related]
4. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.
Colombo R; Caldarelli M; Mennecozzi M; Giorgini ML; Sola F; Cappella P; Perrera C; Depaolini SR; Rusconi L; Cucchi U; Avanzi N; Bertrand JA; Bossi RT; Pesenti E; Galvani A; Isacchi A; Colotta F; Donati D; Moll J
Cancer Res; 2010 Dec; 70(24):10255-64. PubMed ID: 21159646
[TBL] [Abstract][Full Text] [Related]
5. Multiple actions of NMS-P715, the monopolar spindle 1 (MPS1) mitotic checkpoint inhibitor in liver fluke-associated cholangiocarcinoma cells.
Waenphimai O; Mahalapbutr P; Vaeteewoottacharn K; Wongkham S; Sawanyawisuth K
Eur J Pharmacol; 2022 May; 922():174899. PubMed ID: 35337815
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
7. MPS1 kinase as a potential therapeutic target in medulloblastoma.
Alimova I; Ng J; Harris P; Birks D; Donson A; Taylor MD; Foreman NK; Venkataraman S; Vibhakar R
Oncol Rep; 2016 Nov; 36(5):2633-2640. PubMed ID: 27633003
[TBL] [Abstract][Full Text] [Related]
8. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
[TBL] [Abstract][Full Text] [Related]
9. Insights into Resistance Mechanisms of Inhibitors to Mps1 C604Y Mutation via a Comprehensive Molecular Modeling Study.
Chen Y; Yu W; Jiang CC; Zheng JG
Molecules; 2018 Jun; 23(6):. PubMed ID: 29925769
[TBL] [Abstract][Full Text] [Related]
10. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
Martinez R; Blasina A; Hallin JF; Hu W; Rymer I; Fan J; Hoffman RL; Murphy S; Marx M; Yanochko G; Trajkovic D; Dinh D; Timofeevski S; Zhu Z; Sun P; Lappin PB; Murray BW
PLoS One; 2015; 10(9):e0138616. PubMed ID: 26398286
[TBL] [Abstract][Full Text] [Related]
11. Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
Gurden MD; Westwood IM; Faisal A; Naud S; Cheung KM; McAndrew C; Wood A; Schmitt J; Boxall K; Mak G; Workman P; Burke R; Hoelder S; Blagg J; Van Montfort RL; Linardopoulos S
Cancer Res; 2015 Aug; 75(16):3340-54. PubMed ID: 26202014
[TBL] [Abstract][Full Text] [Related]
12. Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells.
Kaistha BP; Honstein T; Müller V; Bielak S; Sauer M; Kreider R; Fassan M; Scarpa A; Schmees C; Volkmer H; Gress TM; Buchholz M
Br J Cancer; 2014 Oct; 111(9):1780-7. PubMed ID: 25137017
[TBL] [Abstract][Full Text] [Related]
13. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
[TBL] [Abstract][Full Text] [Related]
14. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
Jemaà M; Manic G; Lledo G; Lissa D; Reynes C; Morin N; Chibon F; Sistigu A; Castedo M; Vitale I; Kroemer G; Abrieu A
Oncotarget; 2016 Jan; 7(1):885-901. PubMed ID: 26637805
[TBL] [Abstract][Full Text] [Related]
15. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
Sero V; Tavanti E; Vella S; Hattinger CM; Fanelli M; Michelacci F; Versteeg R; Valsasina B; Gudeman B; Picci P; Serra M
Invest New Drugs; 2014 Dec; 32(6):1167-80. PubMed ID: 25193492
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma.
Wang S; Xiong Y; Luo Y; Shen Y; Zhang F; Lan H; Pang Y; Wang X; Li X; Zheng X; Lu X; Liu X; Cheng Y; Wu T; Dong Y; Lu Y; Cui J; Jia X; Yang S; Wang L; Wang Y
EMBO Mol Med; 2024 May; 16(5):1115-1142. PubMed ID: 38570712
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.
Faisal A; Mak GWY; Gurden MD; Xavier CPR; Anderhub SJ; Innocenti P; Westwood IM; Naud S; Hayes A; Box G; Valenti MR; De Haven Brandon AK; O'Fee L; Schmitt J; Woodward HL; Burke R; vanMontfort RLM; Blagg J; Raynaud FI; Eccles SA; Hoelder S; Linardopoulos S
Br J Cancer; 2017 Apr; 116(9):1166-1176. PubMed ID: 28334731
[TBL] [Abstract][Full Text] [Related]
18. Characterization of novel MPS1 inhibitors with preclinical anticancer activity.
Jemaà M; Galluzzi L; Kepp O; Senovilla L; Brands M; Boemer U; Koppitz M; Lienau P; Prechtl S; Schulze V; Siemeister G; Wengner AM; Mumberg D; Ziegelbauer K; Abrieu A; Castedo M; Vitale I; Kroemer G
Cell Death Differ; 2013 Nov; 20(11):1532-45. PubMed ID: 23933817
[TBL] [Abstract][Full Text] [Related]
19. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
[TBL] [Abstract][Full Text] [Related]
20. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.
Wengner AM; Siemeister G; Koppitz M; Schulze V; Kosemund D; Klar U; Stoeckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Raschke M; Frisk AL; von Ahsen O; Michels M; Kreft B; von Nussbaum F; Brands M; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2016 Apr; 15(4):583-92. PubMed ID: 26832791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
